RUNX3 and neoplasm: Although it is not clear how CADD522 is more specific for RUNX2 inhibition, it could be speculated that different three-dimensional architecture and dynamics in response to RUNX protein-cofactor binding or altered efficacy in RUNX1- or RUNX3-DNA binding relative to RUNX2 might influence CADD522 fit into the DNA-Runt binding pocket, which would yield a distinctive DNA binding affinity among RUNX proteins [23], and may have directly contributed to delay of tumor growth.